Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

08. September 2016 08:03 ET | Quelle: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Present at Rodman & Renshaw’s 18th Annual Global Investment Conference

CORAL GABLES, Fla., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative...
02. September 2016 10:40 ET | Quelle: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces FDA Orphan Drug Designation of Firdapse for the Treatment of Myasthenia Gravis

CORAL GABLES, Fla., Sept. 02, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing...
09. August 2016 16:16 ET | Quelle: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Second Quarter 2016 Financial Results and Provides Product Development Update

CORAL GABLES, Fla., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative...
01. August 2016 08:03 ET | Quelle: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Hold Second Quarter Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 10th, 2016

CORAL GABLES, Fla., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative...
13. Juni 2016 08:03 ET | Quelle: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Agreement with FDA on Confirmatory Phase 3 Study Protocol for Firdapse in Lambert-Eaton Myasthenic Syndrome

CORAL GABLES, Fla., June 13, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies...
01. Juni 2016 08:03 ET | Quelle: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference

CORAL GABLES, Fla., June 01, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies...
18. Mai 2016 08:03 ET | Quelle: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceutical’s Firdapse Phase 3 Study Published in Muscle & Nerve

CORAL GABLES, Fla., May 18, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies...
17. Mai 2016 08:03 ET | Quelle: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Reduction in Workforce as Part of Operating Expense Management Plan

CORAL GABLES, Fla., May 17, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies...
10. Mai 2016 16:55 ET | Quelle: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces First Quarter 2016 Financial Results and Provides Corporate Update

CORAL GABLES, Fla., May 10, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing...
06. Mai 2016 08:03 ET | Quelle: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Wednesday, May 11th, 2016

CORAL GABLES, Fla., May 06, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies...

Vorherige Seite

Nächste Seite